Compare Cytokinetics Inc (CYTK) vs LyondellBasell Industries NV (LYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs LyondellBasell Industries NV — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.78B), while LyondellBasell Industries NV trades at $63.98 (market cap $20.24B). The key difference: LyondellBasell Industries NV is the larger of the two by market cap, and LyondellBasell Industries NV pays a 6.58% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | LYB | |
|---|---|---|
Market Cap | $10.78B | $20.24B |
Sector | Technology | Basic Materials |
52-Week High | $87.26 | $82.38 |
52-Week Low | $34.31 | $42.28 |
Enterprise Value | $10.88B | $31.83B |
Dividend Yield | — | 6.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
LyondellBasell Industries (LYB) trades at $59.595, down 2.97% on the day, with a bearish technical signal. The company reported a strong Q2 2026 earnings beat ($4.30 EPS vs. $3.44 expected) but faces declining revenue and negative net income margins. Recent news highlights supply disruptions supporting margins, while analyst consensus is a Buy with a $70.56 price target, implying 18% upside.
Outlook is mixed: earnings momentum and undervaluation (P/S 0.62) offer opportunity, but weak profitability and high debt pose risks. The stock's direction hinges on margin sustainability and broader economic conditions affecting chemical demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →
